AbCellera Biologics Inc. Depreciation
AbCellera Biologics Inc. (ABCL) reported Depreciation of $6.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-05
- AbCellera Biologics Inc. depreciation for the quarter ending 2026-06-30 was $6.10M, a 32.61% increase year-over-year.
- AbCellera Biologics Inc. depreciation for the quarter ending 2026-03-31 was $5.92M, a 34.23% increase year-over-year.
- AbCellera Biologics Inc. depreciation for the quarter ending 2025-12-31 was $5.18M, a 146.76% increase year-over-year.
- AbCellera Biologics Inc. depreciation for the quarter ending 2025-09-30 was $4.30M, a 13.16% increase year-over-year.
- AbCellera Biologics Inc. depreciation for fiscal 2025 was $18.44M, a 47.08% increase from fiscal 2024.
- AbCellera Biologics Inc. depreciation for fiscal 2024 was $12.54M, a 1.73% decline from fiscal 2023.
- AbCellera Biologics Inc. depreciation for fiscal 2023 was $12.76M, a 42.50% increase from fiscal 2022.
- AbCellera Biologics Inc. depreciation for fiscal 2022 was $8.95M, a 103.34% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 3 month as first filed | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $6.10M 10-Q · filed 2026-08-05 | $11.98M 10-Q · filed 2026-08-05 | $17.20M derived: sum of 3 quarters · filed 2026-08-05 | $21.50M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $5.92M 10-Q · filed 2026-05-11 | $11.10M derived: sum of 2 quarters · filed 2026-05-11 | $15.40M derived: sum of 3 quarters · filed 2026-05-11 | $20.00M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $5.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $9.48M derived: sum of 2 quarters · filed 2026-02-24 | $14.08M derived: sum of 3 quarters · filed 2026-08-05 | $18.44M 10-K · filed 2026-02-24 | |
| 2025-09-30 | $4.30M 10-Q · filed 2025-11-06 | $8.90M derived: sum of 2 quarters · filed 2026-08-05 | $13.26M 10-Q · filed 2025-11-06 | $15.41M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $4.60M 10-Q · filed 2026-08-05 | $4.50M 10-Q · filed 2025-08-07 | $8.95M 10-Q · filed 2026-08-05 | $11.11M derived: sum of 3 quarters · filed 2026-08-05 | $14.91M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $4.41M 10-Q · filed 2026-05-11 | $6.51M derived: sum of 2 quarters · filed 2026-05-11 | $10.31M derived: sum of 3 quarters · filed 2026-05-11 | $13.71M derived: sum of 4 quarters · filed 2026-05-11 | |
| 2024-12-31 | $2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $5.90M derived: sum of 2 quarters · filed 2026-02-24 | $9.30M derived: sum of 3 quarters · filed 2026-02-24 | $12.54M 10-K · filed 2026-02-24 | |
| 2024-09-30 | $3.80M 10-Q · filed 2025-11-06 | $7.20M derived: sum of 2 quarters · filed 2025-11-06 | $10.44M 10-Q · filed 2025-11-06 | $14.24M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2024-06-30 | $3.40M 10-Q · filed 2025-08-07 | $6.60M 10-Q · filed 2025-08-07 | $10.44M derived: sum of 3 quarters · filed 2026-02-24 | $13.54M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2024-03-31 | $3.15M 10-Q · filed 2025-05-08 | $7.04M derived: sum of 2 quarters · filed 2026-02-24 | $10.14M derived: sum of 3 quarters · filed 2026-02-24 | $13.14M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2023-12-31 | $3.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $6.98M derived: sum of 2 quarters · filed 2026-02-24 | $9.98M derived: sum of 3 quarters · filed 2026-02-24 | $12.76M 10-K · filed 2026-02-24 | |
| 2023-09-30 | $3.10M 10-Q · filed 2024-11-04 | $6.10M derived: sum of 2 quarters · filed 2024-11-04 | $8.87M 10-Q · filed 2024-11-04 | $11.70M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | $3.00M 10-Q · filed 2024-08-06 | $5.81M 10-Q · filed 2024-08-06 | $8.60M derived: sum of 3 quarters · filed 2025-02-27 | $11.10M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | $2.86M 10-Q · filed 2024-05-07 | $5.60M derived: sum of 2 quarters · filed 2025-02-27 | $8.10M derived: sum of 3 quarters · filed 2025-02-27 | $10.40M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | $2.74M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $5.24M derived: sum of 2 quarters · filed 2025-02-27 | $7.54M derived: sum of 3 quarters · filed 2025-02-27 | $8.95M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $2.50M 10-Q · filed 2023-11-02 | $4.80M derived: sum of 2 quarters · filed 2023-11-02 | $6.21M 10-Q · filed 2023-11-02 | $7.53M derived: sum of 4 quarters · filed 2024-02-20 | |
| 2022-06-30 | $2.30M 10-Q · filed 2023-08-03 | $3.68M 10-Q · filed 2023-08-03 | $5.03M derived: sum of 3 quarters · filed 2024-02-20 | $6.23M derived: sum of 4 quarters · filed 2024-02-20 | |
| 2022-03-31 | $1.39M 10-Q · filed 2023-05-04 | $2.73M derived: sum of 2 quarters · filed 2024-02-20 | $3.93M derived: sum of 3 quarters · filed 2024-02-20 | $5.03M derived: sum of 4 quarters · filed 2024-02-20 | |
| 2021-12-31 | $1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $2.54M derived: sum of 2 quarters · filed 2024-02-20 | $3.64M derived: sum of 3 quarters · filed 2024-02-20 | $4.40M 10-K · filed 2024-02-20 | |
| 2021-09-30 | $1.20M 10-Q · filed 2022-11-08 | $2.30M derived: sum of 2 quarters · filed 2022-11-08 | $3.06M 10-Q · filed 2022-11-08 | $3.95M derived: sum of 4 quarters · filed 2023-02-21 | |
| 2021-06-30 | $1.10M 10-Q · filed 2022-08-09 | $1.90M 10-Q · filed 2022-08-09 | $2.75M derived: sum of 3 quarters · filed 2023-02-21 | $2.75M derived: sum of 4 quarters · filed 2023-02-21 | |
| 2021-03-31 | $840.00K 10-Q · filed 2022-05-10 | $1.65M derived: sum of 2 quarters · filed 2023-02-21 | $1.65M derived: sum of 3 quarters · filed 2023-02-21 | $2.75M derived: sum of 4 quarters · filed 2023-02-21 | |
| 2020-12-31 | $810.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $810.00K derived: sum of 2 quarters · filed 2023-02-21 | $1.91M derived: sum of 3 quarters · filed 2023-02-21 | $2.32M 10-K · filed 2023-02-21 | |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-10 | $1.10M derived: sum of 2 quarters · filed 2021-11-10 | $1.51M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $1.10M 10-Q · filed 2021-08-13 | $1.47M 10-Q · filed 2021-08-13 | |||
| 2020-03-31 | $415.00K 10-Q · filed 2021-05-14 | ||||
| 2019-12-31 | $1.60M 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |